COMMUNIQUÉS West-GlobeNewswire

Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors

05/12/2017 - 14:30

CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to [...]

100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression

05/12/2017 - 14:29

BATON ROUGE, La., Dec. 05, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary [...]

Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial

05/12/2017 - 14:15

Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line Trial Results NORCROSS [...]

BIOLIFE4D Comments on New Guidelines for High Blood Pressure in Adults

05/12/2017 - 14:01

CHICAGO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- BIOLIFE4D , a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today commented on a new report from the American [...]

Tyme Provides Update on At-The-Market Financing Activity

05/12/2017 - 14:00

NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq: TYME ), a clinical-stage biotechnology company developing cancer therapeutics, announced it has raised gross proceeds of approximately $5.0 [...]

Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

05/12/2017 - 14:00

NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today [...]

CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

05/12/2017 - 14:00

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ) today announced that Dr. Bill Lundberg, Chief Scientific Officer of CRISPR, is scheduled to present new data [...]

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting

05/12/2017 - 14:00

SAN DIEGO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today presented [...]

Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology

05/12/2017 - 14:00

NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that results of a multi- [...]

Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium

05/12/2017 - 14:00

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs [...]

Intellipharmaceutics Announces Receipt of Nasdaq Notice

05/12/2017 - 14:00

TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI ) (TSX: IPCI ) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, [...]

Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations

05/12/2017 - 13:30

Phase 2 clinical trial planned for 2018, Actimab-MDS intended to be a bridge to a bone marrow transplant, the only curative treatment option for patients with myelodysplastic syndrome Trial principal investigator, Dr. [...]

Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia A and Hemophilia B Phase 1/2 Clinical Trials at 59th American Society of Hematology Annual Meeting and Exposition

05/12/2017 - 13:30

PHILADELPHIA, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Lindsey A. [...]

Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

05/12/2017 - 13:05

Data From First Dosing Cohort Show a 70% Disease Control Rate – Including 30% of Patients with Partial Responses – and Demonstrate a Tolerable Safety Profile Immunovaccine to Host a Conference Call to Review the Results [...]

Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis

05/12/2017 - 13:05

PETALUMA, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the [...]

Photocure ASA: Presentation at the Carnegie Nordic Healthcare Day, New York

05/12/2017 - 13:03

Oslo, Norway, December 5, 2017 - Photocure ASA (OSE: PHO) announced today that the company will present at the Carnegie Nordic Healthcare Day, New York, on 5 December 2017. Presenter will be Ambaw Bellete, President, [...]

ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor

05/12/2017 - 13:01

OBE022 is a first-in-class, oral and selective PGF2alpha receptor antagonist for the potential treatment of preterm labor to delay or prevent preterm birth Geneva, Switzerland and Boston, MA - December 5, 2017 - ObsEva [...]

Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA

05/12/2017 - 13:00

La Chaux-de-Fonds, Switzerland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated data for RP6530 (tenalisib), the Company’s highly selective and orally active dual PI3K delta/ [...]

Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017

05/12/2017 - 13:00

-Company announces vecabrutinib as generic name for SNS-062- -Event on December 9 in Atlanta, GA with Slide Webcast- SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: [...]